{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:42:50Z","timestamp":1777563770617,"version":"3.51.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s11864-021-00859-8","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T12:10:09Z","timestamp":1623067809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Current Status of CAR T Cell Therapy for Leukemias"],"prefix":"10.1007","volume":"22","author":[{"given":"Katherine","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"LaBelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"issue":"1","key":"859_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551.","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"859_CR2","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1002\/cncr.30791","volume":"123","author":"TB Alexander","year":"2017","unstructured":"Alexander TB, Wang L, Inaba H, Triplett BM, Pounds S, Ribeiro RC, et al. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer. 2017;123(19):3791\u20138. https:\/\/doi.org\/10.1002\/cncr.30791.","journal-title":"Cancer."},{"issue":"16","key":"859_CR3","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541\u201352. https:\/\/doi.org\/10.1056\/NEJMra1400972.","journal-title":"N Engl J Med"},{"issue":"13","key":"859_CR4","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/cncr.30003","volume":"122","author":"D Pulte","year":"2016","unstructured":"Pulte D, Jansen L, Castro FA, Brenner H. Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer. 2016;122(13):2031\u201340. https:\/\/doi.org\/10.1002\/cncr.30003.","journal-title":"Cancer."},{"key":"859_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.12.004","volume":"110","author":"G Tamamyan","year":"2017","unstructured":"Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, et al. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017;110:20\u201334. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.12.004.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"224","key":"859_CR6","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"\u2022\u2022 Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. https:\/\/doi.org\/10.1126\/scitranslmed.3008226 This study was the first report of efficacy in 16 patients with r\/r B-ALL treated with a CAR T cell product using the CD28 co-stimulatory domain and led the way for a larger multicenter phase II trial using the same product. This study also was one for the fist to define dignostic criteria for severe CRS.","journal-title":"Sci Transl Med"},{"issue":"16","key":"859_CR7","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1215134.","journal-title":"N Engl J Med"},{"issue":"9967","key":"859_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3.","journal-title":"Lancet."},{"issue":"5","key":"859_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"\u2022\u2022 Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866 This study reported the results from the ELIANA trial, a phase 2, single-cohort, multicenter global study on the efficacy of tisagenlecleucel in 75 patients with r\/r B-ALL.","journal-title":"N Engl J Med"},{"issue":"4","key":"859_CR10","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","volume":"25","author":"MC O\u2019Leary","year":"2019","unstructured":"O\u2019Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2035.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"859_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/10428194.2019.1691201","volume":"61","author":"KE Cahill","year":"2020","unstructured":"Cahill KE, Leukam MJ, Riedell PA. Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. Leuk Lymphoma. 2020;61(4):799\u2013807. https:\/\/doi.org\/10.1080\/10428194.2019.1691201.","journal-title":"Leuk Lymphoma"},{"issue":"Supplement_1","key":"859_CR12","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1182\/blood-2019-129279","volume":"134","author":"S Grupp","year":"2019","unstructured":"Grupp S, Hu Z-H, Zhang Y, Keating A, Pulsipher MA, Philips C, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory children and young adults with acute lymphoblastic leukemia (ALL): real world experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and cellular therapy (CT) registry. Blood. 2019;134(Supplement_1):2619. https:\/\/doi.org\/10.1182\/blood-2019-129279.","journal-title":"Blood"},{"issue":"Supplement_1","key":"859_CR13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2019-130983","volume":"134","author":"S Jaglowski","year":"2019","unstructured":"Jaglowski S, Hu Z-H, Zhang Y, Kamdar M, Ghosh M, Lulla P, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) cellular therapy (CT) registry. Blood. 2019;134(Supplement_1):766. https:\/\/doi.org\/10.1182\/blood-2019-130983.","journal-title":"Blood"},{"issue":"21","key":"859_CR14","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"\u2022 Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414\u201324. https:\/\/doi.org\/10.1182\/bloodadvances.2020003092 This study reports initial experience with tisagenlecleucel in a real-world setting and describes remission rates, survival outcomes, toxicities, and differences between in- and out-of-specification products.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"859_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2020-136674","volume":"136","author":"J Rossoff","year":"2020","unstructured":"Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips CL, Stefanski H, et al. Real-world treatment of pediatric patients with relapsed\/refractory B-cell acute lymphoblastic leukemia using tisagenlecleucel that is out of specification for commercial release. Blood. 2020;136(Supplement 1):42\u20134. https:\/\/doi.org\/10.1182\/blood-2020-136674.","journal-title":"Blood"},{"issue":"6","key":"859_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581\u201390. https:\/\/doi.org\/10.1038\/nm.3838.","journal-title":"Nat Med"},{"issue":"4","key":"859_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415\u201328. https:\/\/doi.org\/10.1016\/j.ccell.2015.09.004.","journal-title":"Cancer Cell"},{"issue":"11","key":"859_CR18","doi-asserted-by":"publisher","first-page":"e816","DOI":"10.1016\/S2352-3026(20)30277-5","volume":"7","author":"T Anagnostou","year":"2020","unstructured":"Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematol. 2020;7(11):e816\u2013e26. https:\/\/doi.org\/10.1016\/S2352-3026(20)30277-5.","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"859_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood-2020-134472","volume":"136","author":"LM Schultz","year":"2020","unstructured":"Schultz LM, Baggott C, Prabhu S, Pacenta H, Phillips CL, Rossoff J, et al. Disease burden impacts outcomes in pediatric and young adult B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel: results from the pediatric real world CAR consortium (PRWCC). Blood. 2020;136(Supplement 1):14\u20135. https:\/\/doi.org\/10.1182\/blood-2020-134472.","journal-title":"Blood"},{"issue":"5","key":"859_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1709919.","journal-title":"N Engl J Med"},{"issue":"1","key":"859_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","volume":"35","author":"K Fousek","year":"2021","unstructured":"Fousek K, Watanabe J, Joseph SK, George A, An X, Byrd TT, et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2021;35(1):75\u201389. https:\/\/doi.org\/10.1038\/s41375-020-0792-2.","journal-title":"Leukemia."},{"issue":"20","key":"859_CR22","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406\u201310. https:\/\/doi.org\/10.1182\/blood-2015-08-665547.","journal-title":"Blood."},{"issue":"12","key":"859_CR23","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1020.","journal-title":"Cancer Discov"},{"issue":"7","key":"859_CR24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165\u201374. https:\/\/doi.org\/10.1182\/blood-2012-06-438002.","journal-title":"Blood."},{"issue":"1","key":"859_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138. https:\/\/doi.org\/10.1038\/nm.4441.","journal-title":"Nat Med"},{"issue":"17","key":"859_CR26","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, et al. CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J Clin Oncol. 2020;38(17):1938\u201350. https:\/\/doi.org\/10.1200\/JCO.19.03279.","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"859_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1182\/blood-2019-129411","volume":"134","author":"LM Schultz","year":"2019","unstructured":"Schultz LM, Muffly LS, Spiegel JY, Ramakrishna S, Hossain N, Baggott C, et al. Phase I trial using CD19\/CD22 bispecific CAR T cells in pediatric and adult acute lymphoblastic leukemia (ALL). Blood. 2019;134(Supplement_1):744. https:\/\/doi.org\/10.1182\/blood-2019-129411.","journal-title":"Blood"},{"issue":"16 Supplement","key":"859_CR28","doi-asserted-by":"publisher","first-page":"CT051-CT","DOI":"10.1158\/1538-7445.Am2020-ct051","volume":"80","author":"H Shalabi","year":"2020","unstructured":"Shalabi H, Yates B, Shahani S, Qin H, HIghfill SL, Panch S, et al. Abstract CT051: safety and efficacy of CD19\/CD22 CAR T cells in children and young adults with relapsed\/refractory ALL. Cancer Res. 2020;80(16 Supplement):CT051-CT. https:\/\/doi.org\/10.1158\/1538-7445.Am2020-ct051.","journal-title":"Cancer Res"},{"issue":"7","key":"859_CR29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","volume":"126","author":"MR Litzow","year":"2015","unstructured":"Litzow MR, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. Blood. 2015;126(7):833\u201341. https:\/\/doi.org\/10.1182\/blood-2014-10-551895.","journal-title":"Blood."},{"issue":"2","key":"859_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11899-019-00501-3","volume":"14","author":"CM McMahon","year":"2019","unstructured":"McMahon CM, Luger SM. Relapsed T cell ALL: current approaches and new directions. Curr Hematol Malig Rep. 2019;14(2):83\u201393. https:\/\/doi.org\/10.1007\/s11899-019-00501-3.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"859_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","volume":"12","author":"LC Fleischer","year":"2019","unstructured":"Fleischer LC, Spencer HT, Raikar SS. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. J Hematol Oncol. 2019;12(1):141. https:\/\/doi.org\/10.1186\/s13045-019-0801-y.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"859_CR32","doi-asserted-by":"publisher","first-page":"101097","DOI":"10.1016\/j.beha.2019.101097","volume":"32","author":"ML Cooper","year":"2019","unstructured":"Cooper ML, DiPersio JF. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies. Best Pract Res Clin Haematol. 2019;32(4):101097. https:\/\/doi.org\/10.1016\/j.beha.2019.101097.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"21","key":"859_CR33","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","volume":"133","author":"D Sanchez-Martinez","year":"2019","unstructured":"Sanchez-Martinez D, Baroni ML, Gutierrez-Aguera F, Roca-Ho H, Blanch-Lombarte O, Gonzalez-Garcia S, et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. 2019;133(21):2291\u2013304. https:\/\/doi.org\/10.1182\/blood-2018-10-882944.","journal-title":"Blood."},{"issue":"12","key":"859_CR34","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, et al. Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017;23(12):1416\u201323. https:\/\/doi.org\/10.1038\/nm.4444.","journal-title":"Nat Med"},{"issue":"9","key":"859_CR35","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ajh.24794","volume":"92","author":"LP Perera","year":"2017","unstructured":"Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, et al. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. Am J Hematol. 2017;92(9):892\u2013901. https:\/\/doi.org\/10.1002\/ajh.24794.","journal-title":"Am J Hematol"},{"issue":"9","key":"859_CR36","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127(9):3462\u201371. https:\/\/doi.org\/10.1172\/JCI94306.","journal-title":"J Clin Invest"},{"key":"859_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fonc.2019.00126","volume":"9","author":"LD Scherer","year":"2019","unstructured":"Scherer LD, Brenner MK, Mamonkin M. Chimeric antigen receptors for T-cell malignancies. Front Oncol. 2019;9:126. https:\/\/doi.org\/10.3389\/fonc.2019.00126.","journal-title":"Front Oncol"},{"issue":"8","key":"859_CR38","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126(8):983\u201392. https:\/\/doi.org\/10.1182\/blood-2015-02-629527.","journal-title":"Blood."},{"issue":"3","key":"859_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130(3):285\u201396. https:\/\/doi.org\/10.1182\/blood-2017-01-761320.","journal-title":"Blood."},{"issue":"9","key":"859_CR40","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"ML Cooper","year":"2018","unstructured":"Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, et al. An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018;32(9):1970\u201383. https:\/\/doi.org\/10.1038\/s41375-018-0065-5.","journal-title":"Leukemia."},{"key":"859_CR41","doi-asserted-by":"publisher","unstructured":"Rasaiyaah J, Georgiadis C, Preece R, Mock U, Qasim W. TCRalphabeta\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight. 2018;3(13). https:\/\/doi.org\/10.1172\/jci.insight.99442.","DOI":"10.1172\/jci.insight.99442"},{"issue":"22","key":"859_CR42","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","volume":"130","author":"FR Appelbaum","year":"2017","unstructured":"Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood. 2017;130(22):2373\u20136. https:\/\/doi.org\/10.1182\/blood-2017-09-797712.","journal-title":"Blood."},{"issue":"5","key":"859_CR43","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1089\/hum.2017.241","volume":"29","author":"S Li","year":"2018","unstructured":"Li S, Tao Z, Xu Y, Liu J, An N, Wang Y, et al. CD33-specific chimeric antigen receptor T cells with different co-stimulators showed potent anti-leukemia efficacy and different phenotype. Hum Gene Ther. 2018;29(5):626\u201339. https:\/\/doi.org\/10.1089\/hum.2017.241.","journal-title":"Hum Gene Ther"},{"issue":"Supplement 1","key":"859_CR44","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","volume":"132","author":"F Liu","year":"2018","unstructured":"Liu F, Cao Y, Pinz K, Ma Y, Wada M, Chen K, et al. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood. 2018;132(Supplement 1):901. https:\/\/doi.org\/10.1182\/blood-2018-99-110579.","journal-title":"Blood"},{"issue":"Supplement 1","key":"859_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2020-134930","volume":"136","author":"L Wang","year":"2020","unstructured":"Wang L, Zhang Y, Anderson E, Kumar R, Lamble AJ, Orentas RJ. CD22 CAR-T induces both CD19 and CD22 surface down-modulation: defining a mechanism of generalized immune evasion and the effects of epigenetic modifiers. Blood. 2020;136(Supplement 1):22\u20133. https:\/\/doi.org\/10.1182\/blood-2020-134930.","journal-title":"Blood"},{"issue":"18","key":"859_CR46","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","volume":"122","author":"A Mardiros","year":"2013","unstructured":"Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122(18):3138\u201348. https:\/\/doi.org\/10.1182\/blood-2012-12-474056.","journal-title":"Blood."},{"issue":"Supplement 1","key":"859_CR47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","volume":"130","author":"L Budde","year":"2017","unstructured":"Budde L, Song JY, Kim Y, Blanchard S, Wagner J, Stein AS, et al. Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial. Blood. 2017;130(Supplement 1):811. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.811.811.","journal-title":"Blood"},{"issue":"Supplement 1","key":"859_CR48","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1182\/blood.V130.Suppl_1.1359.1359","volume":"130","author":"KD Cummins","year":"2017","unstructured":"Cummins KD, Frey N, Nelson AM, Schmidt A, Luger S, Isaacs RE, et al. Treating relapsed\/refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells. Blood. 2017;130(Supplement 1):1359. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.1359.1359.","journal-title":"Blood"},{"key":"859_CR49","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fonc.2020.00697","volume":"10","author":"S Mardiana","year":"2020","unstructured":"Mardiana S, Gill S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front Oncol. 2020;10:697. https:\/\/doi.org\/10.3389\/fonc.2020.00697.","journal-title":"Front Oncol"},{"issue":"11","key":"859_CR50","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1172\/JCI84813","volume":"126","author":"PJ Paszkiewicz","year":"2016","unstructured":"Paszkiewicz PJ, Frassle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest. 2016;126(11):4262\u201372. https:\/\/doi.org\/10.1172\/JCI84813.","journal-title":"J Clin Invest"},{"issue":"3","key":"859_CR51","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","volume":"25","author":"I Diaconu","year":"2017","unstructured":"Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, et al. Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells. Mol Ther. 2017;25(3):580\u201392. https:\/\/doi.org\/10.1016\/j.ymthe.2017.01.011.","journal-title":"Mol Ther"},{"issue":"11","key":"859_CR52","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105(11):4247\u201354. https:\/\/doi.org\/10.1182\/blood-2004-11-4564.","journal-title":"Blood."},{"issue":"25","key":"859_CR53","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322\u201331. https:\/\/doi.org\/10.1182\/blood-2017-02-769208.","journal-title":"Blood."},{"issue":"13 Supplement","key":"859_CR54","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/1538-7445.Am2018-1631","volume":"78","author":"RK Das","year":"2018","unstructured":"Das RK, Storm J, Barrett DM. Abstract 1631: T cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential. Cancer Res. 2018;78(13 Supplement):1631. https:\/\/doi.org\/10.1158\/1538-7445.Am2018-1631.","journal-title":"Cancer Res"},{"issue":"320","key":"859_CR55","doi-asserted-by":"publisher","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","volume":"8","author":"N Singh","year":"2016","unstructured":"Singh N, Perazzelli J, Grupp SA, Barrett DM. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016;8(320):320ra3. https:\/\/doi.org\/10.1126\/scitranslmed.aad5222.","journal-title":"Sci Transl Med"},{"issue":"24","key":"859_CR56","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24):3750\u20139. https:\/\/doi.org\/10.1182\/blood-2014-01-552174.","journal-title":"Blood."},{"issue":"1","key":"859_CR57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"L Gattinoni","year":"2017","unstructured":"Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. T memory stem cells in health and disease. Nat Med. 2017;23(1):18\u201327. https:\/\/doi.org\/10.1038\/nm.4241.","journal-title":"Nat Med"},{"issue":"4","key":"859_CR58","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","volume":"128","author":"M Sabatino","year":"2016","unstructured":"\u2022 Sabatino M, Hu J, Sommariva M, Gautam S, Fellowes V, Hocker JD, et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood. 2016;128(4):519\u201328. https:\/\/doi.org\/10.1182\/blood-2015-11-683847 This pre-clinical study demonstrated that CD19-CAR T cells generated from modified multipotent T memory stem cells (TSCM) had superior anti-tumor responses compared to conventionally generated, and clinically used, CD19-CAR T cells.","journal-title":"Blood"},{"key":"859_CR59","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","volume":"16","author":"S Tyagarajan","year":"2020","unstructured":"Tyagarajan S, Spencer T, Smith J. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials. Mol Ther Methods Clin Dev. 2020;16:136\u201344. https:\/\/doi.org\/10.1016\/j.omtm.2019.11.018.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"Supplement 1","key":"859_CR60","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2018-99-117493","volume":"132","author":"R Gardner","year":"2018","unstructured":"\u2022 Gardner R, Finney O, Brakke H, Rhea S, Hicks R, Doolittle D, et al. Starting T cell and cell product phenotype are associated with durable remission of leukemia following CD19 CAR-T cell immunotherapy. Blood. 2018;132(Supplement 1):4022. https:\/\/doi.org\/10.1182\/blood-2018-99-117493 Analysis of products from the initial phase 1 anti-CD19 CAR T cell trail found that long-term CAR T cell efficacy could be predicted by the starting phenotype and functional characteristics of the initial T cell product.","journal-title":"Blood"},{"issue":"2","key":"859_CR61","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ijc.33212","volume":"148","author":"F Fan","year":"2021","unstructured":"Fan F, Yoo HJ, Stock S, Wang L, Liu Y, Schubert ML, et al. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. Int J Cancer. 2021;148(2):419\u201328. https:\/\/doi.org\/10.1002\/ijc.33212.","journal-title":"Int J Cancer"},{"issue":"11","key":"859_CR62","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","volume":"22","author":"M Ruella","year":"2016","unstructured":"Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, et al. The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res. 2016;22(11):2684\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1527.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"859_CR63","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","volume":"32","author":"W Zheng","year":"2018","unstructured":"Zheng W, O\u2019Hear CE, Alli R, Basham JH, Abdelsamed HA, Palmer LE, et al. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia. 2018;32(5):1157\u201367. https:\/\/doi.org\/10.1038\/s41375-017-0008-6.","journal-title":"Leukemia."},{"key":"859_CR64","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664. https:\/\/doi.org\/10.3389\/fimmu.2019.02664.","journal-title":"Front Immunol"},{"issue":"10","key":"859_CR65","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504\u20136. https:\/\/doi.org\/10.1038\/s41591-018-0146-z.","journal-title":"Nat Med"},{"issue":"1","key":"859_CR66","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"QS Wang","year":"2015","unstructured":"Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23(1):184\u201391. https:\/\/doi.org\/10.1038\/mt.2014.164.","journal-title":"Mol Ther"},{"issue":"11","key":"859_CR67","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1002\/ajh.25235","volume":"93","author":"J Rosenthal","year":"2018","unstructured":"Rosenthal J, Naqvi AS, Luo M, Wertheim G, Paessler M, Thomas-Tikhonenko A, et al. Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia. Am J Hematol. 2018;93(11):E352\u2013E5. https:\/\/doi.org\/10.1002\/ajh.25235.","journal-title":"Am J Hematol"},{"issue":"12","key":"859_CR68","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1038\/s41375-020-0831-z","volume":"34","author":"J Pan","year":"2020","unstructured":"Pan J, Tan Y, Deng B, Tong C, Hua L, Ling Z, et al. Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children. Leukemia. 2020;34(12):3382\u20137. https:\/\/doi.org\/10.1038\/s41375-020-0831-z.","journal-title":"Leukemia."},{"key":"859_CR69","doi-asserted-by":"publisher","unstructured":"Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020;8(2). https:\/\/doi.org\/10.1136\/jitc-2020-001511.","DOI":"10.1136\/jitc-2020-001511"},{"issue":"15_suppl","key":"859_CR70","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1200\/JCO.2019.37.15_suppl.7006","volume":"37","author":"BD Shah","year":"2019","unstructured":"Shah BD, Bishop MR, Oluwole OO, Logan A, Baer MR, Donnellan WB, et al. End of phase I results of ZUMA-3, a phase 1\/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed\/refractory (R\/R) acute lymphoblastic leukemia (ALL). J Clin Oncol. 2019;37(15_suppl):7006. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.7006.","journal-title":"J Clin Oncol"},{"issue":"16","key":"859_CR71","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"issue":"26","key":"859_CR72","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood.2019001641","volume":"134","author":"KJ Curran","year":"2019","unstructured":"Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood. 2019;134(26):2361\u20138. https:\/\/doi.org\/10.1182\/blood.2019001641.","journal-title":"Blood."},{"issue":"22","key":"859_CR73","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","volume":"128","author":"DW Lee III","year":"2016","unstructured":"Lee DW III, Stetler-Stevenson M, Yuan CM, Shah NN, Delbrook C, Yates B, et al. Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation. Blood. 2016;128(22):218. https:\/\/doi.org\/10.1182\/blood.V128.22.218.218.","journal-title":"Blood"},{"issue":"6","key":"859_CR74","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123\u201338. https:\/\/doi.org\/10.1172\/JCI85309.","journal-title":"J Clin Invest"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00859-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-021-00859-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00859-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T13:39:31Z","timestamp":1623418771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-021-00859-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s11864-021-00859-8","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"31 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Katherine Harris declares that she has no conflict of interest. James L. LaBelle declares that he has no conflict of interest. Michael R. Bishop has received research funding from Novartis, Kite Pharma\/Gilead, and CRISPR Therapeutics and has received compensation for service as a consultant from Novartis, Kite Pharma\/Gilead, Bristol-Myers Squibb\/Juno Therapeutics, and Autolus Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"62"}}